Entrada Therapeutics to Present at Goldman Sachs 44th Annual Global Healthcare Conference
06 Junio 2023 - 6:00AM
Entrada Therapeutics, Inc. (Nasdaq: TRDA), a biopharmaceutical
company aiming to transform the lives of patients by establishing
intracellular Endosomal Escape Vehicle (EEV™)-therapeutics as a new
class of medicines, today announced that Dipal Doshi, President and
Chief Executive Officer, will participate in a fireside chat at the
Goldman Sachs 44th Annual Global Healthcare Conference in Dana
Point, CA. The fireside chat will be held on Wednesday, June 14,
2023 at 10:40 a.m. Pacific Time/1:40 p.m. Eastern Time.
A live webcast will be available on the Investor Relations
section of the Company’s website at www.entradatx.com. A replay
will be available on the Entrada website for 90 days following the
event.
About Entrada TherapeuticsEntrada Therapeutics
is a biopharmaceutical company aiming to transform the lives of
patients by establishing a new class of medicines, Endosomal Escape
Vehicle (EEV™)-therapeutics, to engage intracellular targets that
have long been considered inaccessible and undruggable. The
Company’s EEV therapeutics are designed to enable the efficient
intracellular delivery of a wide range of therapeutics into a
variety of organs and tissues, resulting in an improved therapeutic
index. Through its proprietary, highly versatile and modular EEV
platform, Entrada is building a robust development portfolio of
RNA-, antibody- and enzyme-based programs for the potential
treatment of neuromuscular, immunological, ocular and metabolic
diseases, among others. The Company’s lead oligonucleotide programs
include ENTR-601-44 and ENTR-601-45 for the potential treatment of
people living with Duchenne who are exon 44 and 45 skipping
amenable, respectively, as well as our partnered candidate ENTR-701
targeting myotonic dystrophy type 1 (DM1).
For more information about Entrada, please visit our
website, www.entradatx.com, and follow us
on Twitter and LinkedIn.
Investor and Media ContactKarla MacDonaldChief
Corporate Affairs Officerkmacdonald@entradatx.com
Entrada Therapeutics (NASDAQ:TRDA)
Gráfica de Acción Histórica
De May 2024 a Jun 2024
Entrada Therapeutics (NASDAQ:TRDA)
Gráfica de Acción Histórica
De Jun 2023 a Jun 2024